Zhongsheng pharmaceutical industry cooperates with Wuxi apptec to develop 7 first-class new drug projects

Guangdong Zhongsheng Pharmaceutical Co., Ltd (Zhongsheng pharmaceutical) signed a strategic cooperation agreement with Wuxi apptec on July 13, 2015 The cooperation period between the two parties is 5 years The first stage of cooperation is 2015-2019, in which the R & D of class 1.1 small molecule chemical innovative drugs is jointly carried out Before that, Zhongsheng Pharmaceutical Co., Ltd and Wuxi apptec have successively carried out the projects of "zsym003, a new drug for drug-resistant lung cancer", "zsym004, a new drug for tumor treatment", "zsym005 for influenza A and human avian influenza" and "zsym006, a new drug for liver cancer" On June 16, Zhongsheng Pharmaceutical Co., Ltd announced that it would jointly carry out the cooperative research and development project of "zsym007, zsym008 and zsym009, a class of new drugs for the treatment of nonalcoholic steatohepatitis", together with Wuxi apptec The incidence rate of non-alcoholic fatty liver disease is high in developed countries and regions The prevalence rate is about 15% to 40% worldwide Among them, 10 to 20% of non-alcoholic fatty liver patients will develop into non-alcoholic steatohepatitis (NASH) The incidence of NASH is estimated to be 3% to 5% worldwide, but the incidence rate will increase to 22% in the diabetic population What is more notable is NASH About 15-25% of patients will develop cirrhosis It is predicted that Nash will replace hepatitis C as the main disease requiring liver transplantation by 2025 Nash has become an increasingly common chronic liver disease in the world New drugs for NASH treatment have been regarded as a new blue ocean in the future drug market by major pharmaceutical companies around the world Deutsche Bank even estimates that once Nash drugs are listed, their scale in the global market will reach 35-40 billion US dollars by 2025 Nash treatment market has huge potential and broad prospect The etiology of Nash is complex, the pathogenesis is still unclear, and there is no FDA approved drug for the treatment of NASH There is a huge unsatisfied demand in the field of nonalcoholic steatohepatitis It is very important to develop innovative drugs for the treatment of nonalcoholic steatohepatitis Because of the complexity of Nash and the risk of obesity, diabetes and cardiovascular disease, clinicians only use some insulin sensitizers, lipid-lowering drugs and antioxidants to treat Nash, but the effect is very little With the deeper understanding of pathophysiology and molecular biological pathogenesis of Nash, new targeted drugs for the treatment of Nash have gradually entered the clinical research, ushering in the dawn for the treatment of NASH Zsym007, zsym008 and zsym009 are three innovative drugs for the treatment of nonalcoholic steatohepatitis, which are jointly developed by the company and Wuxi Pharmaceutical Co., Ltd according to different action links of Nash and have different unique action mechanisms and independent intellectual property rights Just like hepatitis C treatment, small molecule combination therapy is an important direction of Nash treatment If the curative effect is confirmed by clinical research and approved to market, it will make up for the deficiency in the field of treatment of non-alcoholic fatty hepatitis The treatment of Nash alone or in combination will have better therapeutic effect.